AMIODARON I DISFUNKTsIYa ShchITOVIDNOY ZhELEZY
- Authors: Pavlova T.V1, Bulanova E.Y.1, Duplyakov D.V1
-
Affiliations:
- Issue: No 5 (2013)
- Pages: 92-96
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/280406
- ID: 280406
Cite item
Open Access
Access granted
Abstract
One of the main anti-arrhythmic drugs used in the treatment of patients with atrial fibrillation, is amiodarone. However, amiodarone can cause thyroid dysfunction, and the question of its cancellation or continuation of treatment should be decided individually for each patient. Clinical experience has shown that the choice can be made in favor of the continuation of treatment with original drug in most cases. Development of amiodarone-associated hypothyroidism and euthyroid hyperthyroxinemia is not accompanied by a loss of antiar-rhythmic activity of drug, and its compensation by L-thyroxine is not accompanied by reinitiation of rhythm disturbances. Development of amiodarone-associated hyperthyroidism is associated with loss of antiarrhythmic activity of drug, and its correction - with the restoration of this effect.
Keywords
Full Text
References
- Диагностика и лечение фибрилляции предсердий. Рекомендации ВНОК и ВНОА. 2011.
- Connolly SJ. Meta-analysis of antiarrhythmic drug trials. J Cardiol 2005;45(1):11-7.
- Zipes DP, Camm AJ, Borggrefe M, ACC/AHA/ ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the ACC/AHA Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). Circulation. 2006; 114:385-484.
- Komatsu T, Horiuchi D, Nakamura S, et al. Longterm preventive effect and safety of amiodarone in patients with paroxysmal atrial fibrillation refractory to class I antiarrhythmic agents: analysis based on patient profiles. Pharmacotherapy 1998-18(6 Pt 2):138-45.
- Hilleman D, Miller MA, Parker R, et al. Optimal management of amiodarone therapy: efficacy and side effects. J Am Coll Cardiol 1997;30(3):791-98.
- Джанашия П.Х., Шевченко Н.М., Рыжова Т.В. Роль амиодарона в лечении аритмий // Лечащий врач 2006. № 3. http://www.lvrach. ru.
- Martino E, Bartalena L, Bogazzi F, Bravermanan L. The Effects of Amiodarone on the Thyroid. Endocrine Reviews 2001;22:240-54.
- Романова Е.Н. Сычев О.С. Фибрилляция предсердий и состояние щитовидной железы: взаимосвязь и последствия терапии. Здоровье Украины 2008. № 5/1. С. 16-7.
- Chiovato L, Martino E, Tonacchera M, et al. Studies on the in vitro cytotoxic effect of amio-darone. Endocrinology 1994;134(5):2277-82.
- Kutarski A, Glowniak A, Szczesniak D, Rucinski P. Electrophysiological effects of biatrial pacing evaluated by means of signal-averaged P wave time-domain parameters. The significance of persistent atrial late potentials in right atrium during biatrial pacing. Cardiology 2008;15(1):26-38.
- Свириденко Н.Ю., Платонова Н.М., Молашенко Н.В., Голицин С.П. и др. Состояния, вызванные приемом амиодарона, в практике кардиолога и эндокринолога // Лечащий врач 2004. № 2. http:/ /www.lvrach.ru.
- Сычев О.С., Фролов А.И., Лизогуб С.В. Частота назначения амиодарона // Новости медицины и фармации 2009 (305). http://novosti.mif-ua.com.
- Сердюк С.Е., Бакалов С.А., Голицын С.П. Влияние заместительной терапии L-тироксином // Кардиология 2005. № 2. С. 11-4.
- Канорский С.Г., Старицкий А.Г. Развитие осложнений при назначении генерических препаратов амиодарона // Фарматека 2005. № 6. С. 55-6.
- Pollak PT. Altered metabolite concentrations with amiodarone genetic substitution cannot be observed without monitoring. Can J Cardiol 2001;17(11):1159-63.
Supplementary files
